pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Drugs
by stage
  • Marketed
  • Phase 3
  • Phase 2
  • Phase 1
  • Preclinical
browse
  • Most catalysts
  • Recently active
  • All drugs →
  • Companies
  • Patent cliff
Calendar
what
  • Trial readouts
  • PDUFA dates
  • Approvals
  • Earnings
when
  • Upcoming
  • Month grid
  • Recently passed
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
  • Drugs
  • Calendar
  • Companies
Hubs
  • Topics
  • Patent cliff
  • Publications
  • Readouts
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
Endpoints·49m ago·1 min read
save

Helus Pharma notches successful Phase 3 depression readout

Nov 16, 2026·read at Endpoints ↗

Helus Pharma, part of the budding class of psychedelics companies, said its lead drug improved depression symptoms compared to placebo, but investors appeared slightly skittish about the safety profile. The company said

source

Reporting by Endpoints.

read at Endpoints ↗
sharex / twitterlinkedin

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?

companies & drugs in this story

no entities indexed yet

related stories

  • 3h agoChina's $40k CAR-T; Novartis and Biogen strike dealsEndpoints
  • 3h agoParker Institute's Karen Knudsen: Cancer research has a translation problemEndpoints
  • 4h agoLilly's 14th acquisition of the year is a little-known blood cancer biotechEndpoints
  • 5h agoJ&J to buy eye disease biotech Ollin Biosciences for up to $3.3BEndpoints
  • 6h agoCG Oncology's bladder cancer treatment beats expectations in Phase 3Endpoints